Neurocrine Biosciences Inc at JPMorgan Healthcare Conference Transcript
Okay. We'll go ahead and get started. I want to welcome everyone to the 2020 JPMorgan Health Care Conference. My name's Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. Our next presenting company is Neurocrine, and presenting on behalf of the company is CEO, Kevin Gorman. And Tessa Romero, Matt Bannon from the team are here as well.
Thank you, Anupam, and thank you, JPMorgan, for the opportunity to present today. I will be making forward-looking statements. So I'd like to direct you to our latest SEC filings.
Neurocrine has a long and rich history. For over 25 years, we've been a neuroscience-focused company, but exquisitely focused more in the intersection at neuroendocrinology and neuropsychiatry.
What we aim to do always is to focus on patient populations who have diseases and disorders that have largely gone untreated for decades or not treated at all. It leads to a difficult
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
